Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2014 |
| gptkbp:ATCCode |
L01XC21
|
| gptkbp:brand |
gptkb:Cyramza
|
| gptkbp:CASNumber |
945721-28-8
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:hasMolecularFormula |
C6368H9804N1692O1992S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
ramucirumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGFR-2 antagonist
|
| gptkbp:molecularWeight |
146 kDa
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
bleeding
hypertension proteinuria infusion-related reactions |
| gptkbp:target |
gptkb:VEGFR-2
|
| gptkbp:UNII |
Q1J8A2A3F0
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cancer colorectal cancer hepatocellular carcinoma gastric cancer |
| gptkbp:bfsParent |
gptkb:VEGFR2
gptkb:KDR |
| gptkbp:bfsLayer |
6
|